Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections

Clinical Infectious Diseases

Volumn 47, Issue SUPPL.1, 2008, Pages

  Mohr III, John F ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; DEHYDROPEPTIDASE INHIBITOR; DEXAMETHASONE; ENZYME INHIBITOR; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTEROIDES FRAGILIS; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ERYTHEMA MULTIFORME; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GLOSSITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEADACHE; HEMOLYTIC ANEMIA; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HYPOTENSION; INJECTION SITE REACTION; KIDNEY FAILURE; LEUKOPENIA; LOADING DRUG DOSE; NAUSEA; NEISSERIA MENINGITIDIS; NEUROTOXICITY; NEUTROPENIA; PAIN; PEPTOSTREPTOCOCCUS; PNEUMONIA; PRIORITY JOURNAL; PROTEUS MIRABILIS; PRURITUS; PSEUDOMONAS AERUGINOSA; RASH; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STEVENS JOHNSON SYNDROME; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; THROMBOCYTOSIS; THRUSH; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; VOMITING;

ABDOMINAL ABSCESS; BACTERIA; BACTERIAL INFECTIONS; CROSS INFECTION; HUMANS; INFANT; MENINGITIS, BACTERIAL; PNEUMONIA; SKIN DISEASES, BACTERIAL; THIENAMYCINS;

EID: 51549095679     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/590065     Document Type: Review

References (55)

1. Bradley JS, Garau J, Lode H, Rolston KVI, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11:93-100.
2. Ayalew K, Nambiar S, Yasinskaya Y, Jantausch BA. Carbapenems in pediatrics. Ther Drug Monit 2003; 25:593-9.
3. Shah D, Narang M. Meropenem. Indian Pediatr 2005; 42:443-50.
4. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67:1027-52.
5. Brink AJ, Feldman C, Grolman DC, et al. Appropriate use of the carbapenems. S Afr Med J 2004; 94:857-61.
6. Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999; 74:420-34.
7. Fish DN, Singletary TJ. Meropenem, a new carbapenem antibiotic. Pharmacotherapy 1997; 17:644-69.
8. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs 2000; 59:653-80.
9. Friedland IR, Lutsar I. New antibiotics. Curr Opin Pediatr 1998; 10:41-5.
10. Norrby SR. Carbapenems in serious infections: a risk-benefit assessment. Drug Saf 2000; 22:191-4.
11. Arrieta A. Use of meropenem in the treatment of serious infections in children: review of the current literature. Clin Infect Dis 1997; 24(Suppl 2):S207-12.
12. MERREM I.V. (meropenem for injection) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, 2007.
13. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004; 64:1621-42.
14. Fabian TC, File TM, Embil JM, et al. Meropenem versus imipenemcilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt) 2005; 6:269-82.
15. Embil JM, Soto NE, Melnick DA. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus. Clin Ther 2006; 28:1164-74.
16. Lami JL, Wilson SE, Hopkins JA. Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems. Am Surg 1991; 57:769-74.
17. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995; 88:397-404.
18. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother 1996; 38:523-37.
19. Garau J, Blanquer J, Cobo L, et al. Prospective, randomised,multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997; 16:789-96.
20. Mouton YJ, Beuscart C. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. J Antimicrob Chemother 1995; 36(Suppl A):145-56.
21. Principi N, Marchisio P. Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group. J Chemother 1998; 10:108-13.
22. Jarvis WR, Schlosser J, Chinn RY, Tweeten S, Jackson M. National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at US health care facilities, 2006. Am J Infect Control 2007; 35:631-7.
23. Klevens RM, Morrison MA, Nadle J, Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71.
24. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005.
25. Tellado JM, Wilson SE. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg Infect (Larchmt) 2005; 6:329-43.
26. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995; 35:139-48.
27. Geroulanos SJ. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. J Antimicrob Chemother 1995; 36(Suppl A):191-205.
28. Huizinga WKJ, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995; 36(Suppl A):179-89.
29. Basoli A, Meli EZ, Mazzocchi P, Speranza V. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 1997; 29:503-8.
30. Wilson SE. Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Clin Infect Dis 1997; 24(Suppl 2):S197-206.
31. Berne TV, Yellin AE, Appleman MD, Heseltine PNR, Gill MA. Meropenem versus tobramycin with clindamycin in the antibiotic man agement of patients with advanced appendicitis. J Am Coll Surg 1996; 182:403-7.
32. Kempf P, Bauernfeind A, Müller A, Blum J. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Infection 1996; 24:473-9.
33. Kanellakopoulou K, Giamarellou H, Papadothomakos P, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993; 12:449-53.
34. Verwaest C, Belgian Multicenter Study Group. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000; 6:294-302.
35. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program. Paediatr Drugs 2006; 8:131-8.
36. Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39:1140-6.
37. Odio CM, Puig JR, Feris JM, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999; 18:581-90.
38. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
39. Cunha BA. Nosocomial pneumonia. Diagnostic and therapeutic considerations. Med Clin North Am 2001; 85:79-114.
40. Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 2005; 51:227-33.
41. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med 2005; 33:2222-7.
42. Berman SJ, Fogarty CM, Fabian T, Melnick D, Lesky W, Merrem Hospital-Acquired Pneumonia Study Group. Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. J Chemother 2004; 16:362-71.
43. Santos SS, Machado FR, Kiffer CRV, Barone AA. Treatment of nosocomial pneumonia: an experience with meropenem. Braz J Infect Dis 2001; 5:124-9.
44. Köksal N, Hacimustafaoǧlu M, Baǧci S, Çelebi S. Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. Indian J Pediatr 2001; 68:15-9.
45. Sieger B, Berman SJ, Geckler RW, Farkas SA. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997; 25:1663-70.
46. Alvarez Lerma F, Serious Infection Study Group. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13:70-81.
47. Hou F, Li J, Wu G, et al. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections. Chin Med J (Engl) 2002; 115:1849-54.
48. Jaspers CAJJ, Kieft H, Speelberg B, et al. Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients. Antimicrob Agents Chemother 1998; 42:1233-8.
49. Kotapati S, Nicolau DP, Nightingale CH, Kuti JL. Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2004; 61:1264-70.
50. Thalhammer F, Traunmüller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999; 43:523-7.
51. Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40:219-23.
52. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 46:1171-8.
53. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005; 49:1337-9.
54. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36(Suppl A):207-23.
55. Linden P. Safety profile of meropenem: an updated review of over 6000 patients treated with meropenem. Drug Saf 2007; 30:657-68.